nifedipine has been researched along with clevidipine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gonon, A; Nordlander, M; Rydén, L; Segawa, D; Sjöquist, PO; Wang, QD | 1 |
| Lynch, C; Vivien, B; Yi, X | 1 |
| Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K | 1 |
2 review(s) available for nifedipine and clevidipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalaprilat; Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Hypertension; Infusions, Intravenous; Intracranial Hemorrhages; Labetalol; Nifedipine; Pre-Eclampsia; Pregnancy; Pyridines; Stroke | 2018 |
5 other study(ies) available for nifedipine and clevidipine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine.
Topics: Animals; Calcium Channel Blockers; Cardiotonic Agents; Coronary Circulation; Dihydropyridines; Heart Atria; Heart Block; Heart Rate; Isradipine; Male; Myocardial Contraction; Nifedipine; Pyridines; Rats; Rats, Sprague-Dawley; Systole; Ventricular Function, Left; Ventricular Pressure | 1999 |
Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pig ventricular myocytes.
Topics: Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Electric Stimulation; Electrophysiology; Guinea Pigs; Heart Ventricles; Nifedipine; Patch-Clamp Techniques; Pyridines; Ventricular Function | 2000 |